# New England Journal of Medicine

Source: https://onco.cc/journals/nejm/  
OnCo record `nejm` (Journal). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

NEJM is the most influential medical journal. When a cancer drug trial changes how patients are treated, the paper is usually here, often published the same day it is presented at ASCO, ESMO or ASH.

## Summary

Weekly general-medicine journal with the highest bar for randomised evidence and the largest share of practice-changing oncology phase 3 trials (IRIS imatinib, KEYNOTE-189, DESTINY-Breast04, CheckMate 067, ZUMA-1 and dozens more in this corpus). Editorials and correspondence often carry the critical reading of a trial. Paywalled, with abstracts free and many trial papers free six months after publication; requires a data-sharing statement for clinical trials under ICMJE rules.

## Fields

- Kind: Journal
- Last checked: 2026-09-09
- Also known as: NEJM; N Engl J Med; src-nejm
- Publisher: NEJM Group / Massachusetts Medical Society
- Scope: general medicine
- Access: subscription

## Notes

- Holds: The practice-changing phase 3 trials, most published simultaneously with ASCO, ESMO and ASH presentations. Access: Paywalled; abstracts free; many trial papers free after 6 months.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/The_New_England_Journal_of_Medicine
- Hematology/Oncology specialty page: https://www.nejm.org/browse/specialty/hematology-oncology

## Connected records

- collections: [PubMed & Europe PMC](https://onco.cc/collections/pubmed-europepmc/)
- key papers: [20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years](https://onco.cc/key-papers/paper-pan-n-engl-j-med/), [21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer](https://onco.cc/key-papers/paper-rxponder-n-engl-j-med-2021/), [70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer](https://onco.cc/key-papers/paper-cardoso-n-engl-j-med/), [A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening](https://onco.cc/key-papers/paper-eclipse-shield-n-engl-j-med-2024/), [A gain-of-function mutation of JAK2 in myeloproliferative disorders](https://onco.cc/key-papers/paper-kralovics-n-engl-j-med/), [A pooled analysis of bone marrow micrometastasis in breast cancer](https://onco.cc/key-papers/paper-braun-n-engl-j-med/), [A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer](https://onco.cc/key-papers/paper-espac-1-chemoradiotherapy-chemotherapy-resected-pancreatic-nejm-2004/), [A3961: outcome after reduced chemotherapy for intermediate-risk neuroblastoma](https://onco.cc/key-papers/paper-a3961-intermediate-risk-neuroblastoma-baker-nejm-2010/), [ABC-02: cisplatin plus gemcitabine versus gemcitabine alone for biliary tract cancer](https://onco.cc/key-papers/paper-abc-02-gemcitabine-cisplatin-nejm-2010/), [Abiraterone in metastatic prostate cancer without previous chemotherapy](https://onco.cc/key-papers/paper-abiraterone-acetate-prostate-n-engl-j-med-2013/), [Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia](https://onco.cc/key-papers/paper-acalabrutinib-cll-n-engl-j-med-2016/), [Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib](https://onco.cc/key-papers/paper-lynch-egfr-activating-mutations-gefitinib-nejm-2004/), [Acute lymphoblastic leukaemia in children (review)](https://onco.cc/key-papers/paper-hunger-mullighan-all-children-nejm-2015/), [Acute Myeloid Leukemia](https://onco.cc/key-papers/paper-dohner-n-engl-j-med/), [Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS G12C Mutation](https://onco.cc/key-papers/paper-nct03785249-n-engl-j-med-2022/), [ADAURA: three years of osimertinib after surgery for EGFR-mutated lung cancer](https://onco.cc/key-papers/paper-adaura-nejm-2020/), [Adenocarcinoma of the vagina: association of maternal stilbestrol therapy with tumour appearance in young women](https://onco.cc/key-papers/paper-herbst-diethylstilbestrol-vaginal-adenocarcinoma-nejm-1971/), [Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy](https://onco.cc/key-papers/paper-create-x-adjuvant-capecitabine-nejm-2017/), [Adjuvant ovarian suppression in premenopausal breast cancer](https://onco.cc/key-papers/paper-soft-text-n-engl-j-med-2015/), [Adjuvant trastuzumab in HER2-positive breast cancer](https://onco.cc/key-papers/paper-trastuzumab-breast-her2-positive-n-engl-j-med-2011/), [ADMIRAL: gilteritinib pills versus chemotherapy for relapsed FLT3-mutated acute myeloid leukaemia](https://onco.cc/key-papers/paper-admiral-gilteritinib-flt3-nejm-2019/), [ADRIATIC: durvalumab after chemoradiotherapy for limited-stage small-cell lung cancer](https://onco.cc/key-papers/paper-adriatic-nejm-2024/), [AFFIRM: increased survival with enzalutamide in prostate cancer after chemotherapy](https://onco.cc/key-papers/paper-scher-affirm-enzalutamide-nejm-2012/), [AGILE: ivosidenib plus azacitidine for newly diagnosed IDH1-mutated AML in patients unfit for intensive chemotherapy](https://onco.cc/key-papers/paper-agile-ivosidenib-azacitidine-nejm-2022/), [AHOD1331: brentuximab vedotin with chemotherapy in paediatric high-risk Hodgkin lymphoma](https://onco.cc/key-papers/paper-ahod1331-brentuximab-vedotin-paediatric-hodgkin-castellino-nejm-2022/), [Alectinib in resected ALK-positive non-small-cell lung cancer](https://onco.cc/key-papers/paper-wu-alina-adjuvant-alectinib-nejm-2024/), [Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer](https://onco.cc/key-papers/paper-peters-alex-alectinib-crizotinib-nejm-2017/), [ALSYMPCA: alpha emitter radium-223 and survival in metastatic prostate cancer with bone metastases](https://onco.cc/key-papers/paper-alsympca-radium-223-nejm-2013/), [Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions](https://onco.cc/key-papers/paper-nct04538664-n-engl-j-med-2023/), [AMPLIFY: fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, versus chemo-immunotherapy in fit CLL patients](https://onco.cc/key-papers/paper-amplify-acalabrutinib-venetoclax-nejm-2025/), [Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer](https://onco.cc/key-papers/paper-chan-n-engl-j-med/), [Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer](https://onco.cc/key-papers/paper-kwak-crizotinib-alk-nsclc-nejm-2010/), [ANCHOR: treating anal high-grade squamous intraepithelial lesions to prevent anal cancer in people living with HIV](https://onco.cc/key-papers/paper-anchor-anal-hsil-treatment-nejm-2022/), [Anti-GD2 antibody with GM-CSF, interleukin-2 and isotretinoin for high-risk neuroblastoma (COG ANBL0032)](https://onco.cc/key-papers/paper-yu-anti-gd2-neuroblastoma-nejm-2010/), [Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer](https://onco.cc/key-papers/paper-nct02489318-n-engl-j-med-2019/), [APHINITY: adjuvant pertuzumab added to trastuzumab and chemotherapy in early HER2-positive breast cancer](https://onco.cc/key-papers/paper-aphinity-nejm-2017/), [APL0406: retinoic acid plus arsenic trioxide without chemotherapy for low- and intermediate-risk acute promyelocytic leukaemia](https://onco.cc/key-papers/paper-apl0406-lo-coco-nejm-2013/), [APT: adjuvant paclitaxel and trastuzumab for small, node-negative HER2-positive breast cancer](https://onco.cc/key-papers/paper-apt-tolaney-nejm-2015/), [AQUILA: daratumumab versus active monitoring in high-risk smouldering multiple myeloma](https://onco.cc/key-papers/paper-aquila-daratumumab-smouldering-nejm-2025/), [AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer](https://onco.cc/key-papers/paper-antonarakis-ar-v7-resistance-nejm-2014/), [ARAMIS: darolutamide in non-metastatic castration-resistant prostate cancer](https://onco.cc/key-papers/paper-aramis-nejm-2019/), [ARASENS: darolutamide added to androgen deprivation and docetaxel in metastatic hormone-sensitive prostate cancer](https://onco.cc/key-papers/paper-arasens-nejm-2022/), [ARID1A mutations in endometriosis-associated ovarian carcinomas](https://onco.cc/key-papers/paper-wiegand-arid1a-clear-cell-nejm-2010/), [ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer](https://onco.cc/key-papers/paper-ascent-nejm-2021/), [Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer](https://onco.cc/key-papers/paper-impassion130-n-engl-j-med-2018/), [Atezolizumab for advanced alveolar soft part sarcoma](https://onco.cc/key-papers/paper-atezolizumab-alveolar-soft-part-sarcoma-chen-nejm-2023/), [Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC](https://onco.cc/key-papers/paper-herbst-impower110-atezolizumab-pd-l1-nejm-2020/), [Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer](https://onco.cc/key-papers/paper-atomic-n-engl-j-med-2026/), [Beamion LUNG-1: zongertinib in previously treated HER2-mutant non-small-cell lung cancer](https://onco.cc/key-papers/paper-beamion-lung-1-zongertinib-nejm-2025/), [Belzutifan for renal cell carcinoma and other tumours in von Hippel-Lindau disease](https://onco.cc/key-papers/paper-belzutifan-vhl-jonasch-nejm-2021/), [Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma](https://onco.cc/key-papers/paper-olivier-chinot-n-engl-j-med-2014/), [Blinatumomab added to chemotherapy in infant KMT2A-rearranged acute lymphoblastic leukaemia](https://onco.cc/key-papers/paper-blinatumomab-infant-all-van-der-sluis-nejm-2023/), [Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia](https://onco.cc/key-papers/paper-blinatumomab-all-leukemia-n-engl-j-med-2017/), [BRAF mutations in hairy-cell leukemia](https://onco.cc/key-papers/paper-tiacci-n-engl-j-med/), [BREAKWATER: encorafenib plus cetuximab with chemotherapy as first treatment for BRAF V600E-mutated colorectal cancer](https://onco.cc/key-papers/paper-breakwater-nejm-2025/), [Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer](https://onco.cc/key-papers/paper-kunkler-n-engl-j-med/), [Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer](https://onco.cc/key-papers/paper-alta-1l-n-engl-j-med-2018/), [BRIM-3: improved survival with vemurafenib in melanoma with BRAF V600E mutation](https://onco.cc/key-papers/paper-chapman-vemurafenib-nejm-2011/), [C-POST: adjuvant cemiplimab versus placebo in high-risk cutaneous squamous cell carcinoma](https://onco.cc/key-papers/paper-c-post-adjuvant-cemiplimab-nejm-2025/), [CABINET (Alliance A021602): cabozantinib for advanced neuroendocrine tumours](https://onco.cc/key-papers/paper-cabinet-cabozantinib-nejm-2024/), [CAPItello-291: capivasertib plus fulvestrant in hormone receptor-positive advanced breast cancer](https://onco.cc/key-papers/paper-capitello-291-nejm-2023/), [Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer](https://onco.cc/key-papers/paper-wolf-geometry-mono-1-capmatinib-nejm-2020/), [Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma](https://onco.cc/key-papers/paper-lenalidomide-multiple-myeloma-n-engl-j-med-2015/), [CARTITUDE-4: cilta-cel CAR-T versus standard combinations after one to three prior lines of myeloma therapy](https://onco.cc/key-papers/paper-cartitude-4-cilta-cel-nejm-2023/), [Cercek 2022: six months of dostarlimab alone made rectal cancer disappear in every patient with mismatch-repair deficiency](https://onco.cc/key-papers/paper-cercek-dostarlimab-rectal-nejm-2022/), [Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer (CRYSTAL)](https://onco.cc/key-papers/paper-van-cutsem-crystal-cetuximab-folfiri-nejm-2009/), [CHAARTED: chemohormonal therapy in metastatic hormone-sensitive prostate cancer](https://onco.cc/key-papers/paper-chaarted-nejm-2015/), [CHALLENGE: a structured exercise programme after chemotherapy improves survival in colon cancer](https://onco.cc/key-papers/paper-challenge-exercise-nejm-2025/), [CheckMate 026: first-line nivolumab in stage IV or recurrent non-small-cell lung cancer](https://onco.cc/key-papers/paper-checkmate-026-first-line-nivolumab-nejm-2017/), [CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma](https://onco.cc/key-papers/paper-checkmate-067-10-year-nejm-2025/), [CheckMate 141: nivolumab for recurrent head and neck squamous cell carcinoma after platinum](https://onco.cc/key-papers/paper-checkmate-141-ferris-nejm-2016/), [CheckMate 214: nivolumab plus ipilimumab versus sunitinib in advanced renal cell carcinoma](https://onco.cc/key-papers/paper-checkmate-214-nejm-2018/), [CheckMate 238: adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma](https://onco.cc/key-papers/paper-checkmate-238-nejm-2017/), [CheckMate 577: adjuvant nivolumab in resected oesophageal or gastro-oesophageal junction cancer](https://onco.cc/key-papers/paper-checkmate-577-nejm-2021/), [CheckMate 648: nivolumab combination therapy in advanced oesophageal squamous cell carcinoma](https://onco.cc/key-papers/paper-checkmate-648-nejm-2022/), [CheckMate 816: three cycles of nivolumab plus chemotherapy before lung cancer surgery](https://onco.cc/key-papers/paper-checkmate-816-nejm-2022/), [Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction](https://onco.cc/key-papers/paper-macdonald-n-engl-j-med/), [Children's Oncology Group AALL1731: blinatumomab added to chemotherapy for children with standard-risk B-cell ALL](https://onco.cc/key-papers/paper-aall1731-blinatumomab-children-nejm-2025/), [Chronic health conditions in adult survivors of childhood cancer](https://onco.cc/key-papers/paper-oeffinger-n-engl-j-med/), [Circulating tumor cells, disease progression, and survival in metastatic breast cancer](https://onco.cc/key-papers/paper-cristofanilli-n-engl-j-med/), [CLARINET: lanreotide in metastatic enteropancreatic neuroendocrine tumours](https://onco.cc/key-papers/paper-clarinet-lanreotide-nejm-2014/), [CLEAR: lenvatinib plus pembrolizumab versus sunitinib as first treatment for advanced kidney cancer](https://onco.cc/key-papers/paper-clear-nejm-2021/), [CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients](https://onco.cc/key-papers/paper-cll14-venetoclax-obinutuzumab-nejm-2019/), [CodeBreaK 100: sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer](https://onco.cc/key-papers/paper-codebreak-100-sotorasib-kras-g12c-pancreatic-nejm-2023/), [CodeBreaK 300: sotorasib plus panitumumab in chemotherapy-refractory KRAS G12C colorectal cancer](https://onco.cc/key-papers/paper-codebreak-300-nejm-2023/), [Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths (National Polyp Study)](https://onco.cc/key-papers/paper-zauber-national-polyp-study-colonoscopic-polypectomy-nejm-2012/), [COMBI-AD: adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma](https://onco.cc/key-papers/paper-combi-ad-nejm-2017/), [Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma](https://onco.cc/key-papers/paper-combi-d-n-engl-j-med-2014/), [Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain](https://onco.cc/key-papers/paper-checkmate-204-n-engl-j-med-2018/), [Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma](https://onco.cc/key-papers/paper-nivolumab-melanoma-n-engl-j-med-2015/), [Combined vemurafenib and cobimetinib in BRAF-mutated melanoma](https://onco.cc/key-papers/paper-cobrim-n-engl-j-med-2014/), [COMFORT-I: ruxolitinib, the first JAK inhibitor, versus placebo for myelofibrosis](https://onco.cc/key-papers/paper-comfort-1-ruxolitinib-myelofibrosis-nejm-2012/), [COMFORT-II: JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis](https://onco.cc/key-papers/paper-comfort-ii-ruxolitinib-best-available-therapy-harrison-nejm-2012/), [Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer](https://onco.cc/key-papers/paper-schiller-ecog-1594-four-chemotherapy-regimens-nejm-2002/), [Compliance with results reporting at ClinicalTrials.gov](https://onco.cc/key-papers/paper-anderson-n-engl-j-med/), [Comprehensive molecular characterisation of papillary renal cell carcinoma (The Cancer Genome Atlas)](https://onco.cc/key-papers/paper-tcga-papillary-rcc-nejm-2016/), [COU-AA-301: abiraterone and increased survival in metastatic castration-resistant prostate cancer after docetaxel](https://onco.cc/key-papers/paper-cou-aa-301-abiraterone-de-bono-nejm-2011/), [Crizotinib in ROS1-rearranged non-small-cell lung cancer](https://onco.cc/key-papers/paper-shaw-crizotinib-ros1-nejm-2014/), [Crizotinib versus chemotherapy in advanced ALK-positive lung cancer](https://onco.cc/key-papers/paper-alk-nsclc-n-engl-j-med-2013/), [CROSS: preoperative chemoradiotherapy for oesophageal or junctional cancer](https://onco.cc/key-papers/paper-cross-nejm-2012/), [Cytoplasmic nucleophosmin in acute myeloid leukaemia with a normal karyotype](https://onco.cc/key-papers/paper-falini-npm1-nejm-2005/), [Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations](https://onco.cc/key-papers/paper-bouffet-n-engl-j-med/), [Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma](https://onco.cc/key-papers/paper-lenalidomide-multiple-myeloma-n-engl-j-med-2016/), [Daraxonrasib in Previously Treated Advanced RAS -Mutated Pancreatic Cancer](https://onco.cc/key-papers/paper-nct05379985-n-engl-j-med-2026/), [Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer](https://onco.cc/key-papers/paper-daraxonrasib-pancreatic-n-engl-j-med-2026/), [Deletion of IKZF1 and prognosis in acute lymphoblastic leukaemia](https://onco.cc/key-papers/paper-mullighan-ikzf1-nejm-2009/), [DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer](https://onco.cc/key-papers/paper-dellphi-301-nejm-2023/), [Department of Veterans Affairs Laryngeal Cancer Study: induction chemotherapy plus radiation versus surgery plus radiation](https://onco.cc/key-papers/paper-va-larynx-induction-chemotherapy-nejm-1991/), [DESKTOP III: secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancer](https://onco.cc/key-papers/paper-desktop-iii-nejm-2021/), [DESTINY-Breast03: trastuzumab deruxtecan beats T-DM1 as second-line treatment of HER2-positive metastatic breast cancer](https://onco.cc/key-papers/paper-destiny-breast03-nejm-2022/), [DESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group](https://onco.cc/key-papers/paper-destiny-breast04-nejm-2022/), [DESTINY-Breast06: trastuzumab deruxtecan before any chemotherapy in hormone-receptor-positive, HER2-low or ultralow breast cancer](https://onco.cc/key-papers/paper-destiny-breast06-nejm-2024/), [DESTINY-Gastric01: trastuzumab deruxtecan in previously treated HER2-positive gastric cancer](https://onco.cc/key-papers/paper-destiny-gastric01-nejm-2020/), [DESTINY-Lung01: trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer](https://onco.cc/key-papers/paper-destiny-lung01-nejm-2022/), [Distinct sets of genetic alterations in melanoma](https://onco.cc/key-papers/paper-curtin-melanoma-genetic-alterations-nejm-2005/), [Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma](https://onco.cc/key-papers/paper-dunleavy-da-epoch-r-pmbcl-nejm-2013/), [Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory acute myeloid leukaemia](https://onco.cc/key-papers/paper-ivosidenib-idh1-dinardo-nejm-2018/), [Duration of adjuvant chemotherapy for stage III colon cancer (the IDEA collaboration)](https://onco.cc/key-papers/paper-idea-duration-adjuvant-stage-iii-colon-nejm-2018/), [DYNAMIC: a blood test safely halved chemotherapy use after surgery for stage II colon cancer](https://onco.cc/key-papers/paper-dynamic-nejm-2022/), [ECHELON-1: brentuximab vedotin replacing bleomycin in first-line chemotherapy for advanced Hodgkin lymphoma](https://onco.cc/key-papers/paper-echelon-1-brentuximab-avd-nejm-2018/), [ECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission](https://onco.cc/key-papers/paper-e1910-blinatumomab-mrd-negative-all-nejm-2024/), [Effect of Aspirin on All-Cause Mortality in the Healthy Elderly](https://onco.cc/key-papers/paper-mcneil-n-engl-j-med/), [Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease](https://onco.cc/key-papers/paper-caret-beta-carotene-retinol-lung-cancer-nejm-1996/), [Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumours](https://onco.cc/key-papers/paper-demetri-imatinib-gist-nejm-2002/), [Efficacy and safety of midostaurin in advanced systemic mastocytosis](https://onco.cc/key-papers/paper-gotlib-midostaurin-advanced-systemic-mastocytosis-nejm-2016/), [EGFR mutation and resistance of non-small-cell lung cancer to gefitinib](https://onco.cc/key-papers/paper-kobayashi-egfr-t790m-gefitinib-resistance-nejm-2005/), [Elective versus therapeutic neck dissection in node-negative oral cancer](https://onco.cc/key-papers/paper-dcruz-elective-neck-dissection-nejm-2015/), [ELIANA: the global trial that made tisagenlecleucel the first approved CAR-T therapy for children and young adults with relapsed ALL](https://onco.cc/key-papers/paper-eliana-tisagenlecleucel-nejm-2018/), [Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer](https://onco.cc/key-papers/paper-nct05587296-n-engl-j-med-2025/), [EMBARK: enzalutamide with or without leuprolide in high-risk biochemically recurrent prostate cancer](https://onco.cc/key-papers/paper-embark-nejm-2023/), [EMPOWER-Cervical 1: cemiplimab versus chemotherapy in recurrent cervical cancer after platinum](https://onco.cc/key-papers/paper-empower-cervical-1-cemiplimab-nejm-2022/), [Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer (BEACON CRC)](https://onco.cc/key-papers/paper-kopetz-beacon-encorafenib-braf-colorectal-nejm-2019/), [eNRGy: efficacy of zenocutuzumab in NRG1 fusion-positive cancer](https://onco.cc/key-papers/paper-enrgy-zenocutuzumab-nrg1-fusion-positive-cancer-nejm-2025/), [Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer](https://onco.cc/key-papers/paper-enzamet-n-engl-j-med-2019/), [EORTC 22863: improved survival with radiotherapy plus goserelin in locally advanced prostate cancer](https://onco.cc/key-papers/paper-bolla-eortc-22863-nejm-1997/), [EORTC 22931: postoperative irradiation with or without concomitant cisplatin for locally advanced head and neck cancer](https://onco.cc/key-papers/paper-bernier-eortc-22931-nejm-2004/), [ERIVANCE BCC: efficacy and safety of vismodegib in advanced basal cell carcinoma](https://onco.cc/key-papers/paper-erivance-vismodegib-sekulic-nejm-2012/), [ERSPC: screening and prostate cancer mortality in a randomised European study](https://onco.cc/key-papers/paper-schroder-erspc-screening-mortality-nejm-2009/), [ESTIMABL2: thyroidectomy without radioiodine in patients with low-risk thyroid cancer](https://onco.cc/key-papers/paper-estimabl2-leboulleux-nejm-2022/), [EV-302: enfortumab vedotin plus pembrolizumab replaces chemotherapy as first treatment for advanced bladder cancer](https://onco.cc/key-papers/paper-ev-302-nejm-2024/), [Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer](https://onco.cc/key-papers/paper-bolero-2-n-engl-j-med-2012/), [EXTREME: platinum-based chemotherapy plus cetuximab in recurrent or metastatic head and neck cancer](https://onco.cc/key-papers/paper-extreme-vermorken-nejm-2008/), [FDA's Project Optimus manifesto: cancer drugs are approved at doses that are too high](https://onco.cc/key-papers/paper-drug-dosing-conundrum-nejm-2021/), [FIRM-ACT: combination chemotherapy in advanced adrenocortical carcinoma](https://onco.cc/key-papers/paper-firm-act-edp-mitotane-adrenocortical-carcinoma-nejm-2012/), [First imatinib trial: a pill that switched off the enzyme driving chronic myeloid leukaemia](https://onco.cc/key-papers/paper-druker-imatinib-phase1-nejm-2001/), [First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer](https://onco.cc/key-papers/paper-impower133-n-engl-j-med-2018/), [First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer](https://onco.cc/key-papers/paper-serena-6-n-engl-j-med-2025/), [First-line crizotinib versus chemotherapy in ALK-positive lung cancer](https://onco.cc/key-papers/paper-solomon-n-engl-j-med/), [First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer](https://onco.cc/key-papers/paper-shaw-crown-lorlatinib-crizotinib-nejm-2020/), [First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations](https://onco.cc/key-papers/paper-nct05668988-n-engl-j-med-2026/), [Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma](https://onco.cc/key-papers/paper-combi-ad-n-engl-j-med-2020-update/), [FLAURA: osimertinib as first treatment for EGFR-mutated lung cancer](https://onco.cc/key-papers/paper-flaura-nejm-2018/), [GALLIUM: obinutuzumab for the first-line treatment of follicular lymphoma](https://onco.cc/key-papers/paper-gallium-obinutuzumab-first-line-follicular-lymphoma-marcus-nejm-2017/), [Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma](https://onco.cc/key-papers/paper-mok-ipass-gefitinib-pulmonary-adenocarcinoma-nejm-2009/), [Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR](https://onco.cc/key-papers/paper-egfr-nsclc-n-engl-j-med-2010/), [Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma](https://onco.cc/key-papers/paper-zhang-gemcitabine-cisplatin-induction-nasopharyngeal-nejm-2019/), [Genetic alterations during colorectal-tumor development](https://onco.cc/key-papers/paper-vogelstein-genetic-alterations-colorectal-tumor-development-nejm-1988/), [Genetics and pathogenesis of diffuse large B-cell lymphoma](https://onco.cc/key-papers/paper-schmitz-genetics-pathogenesis-dlbcl-nejm-2018/), [Gerlinger: a single biopsy misses most of the mutations in a kidney tumour](https://onco.cc/key-papers/paper-gerlinger-intratumour-heterogeneity-nejm-2012/), [Germline mutations in nonsyndromic pheochromocytoma](https://onco.cc/key-papers/paper-neumann-germline-mutations-nonsyndromic-pheochromocytoma-nejm-2002/), [GHSG HD10: reduced treatment intensity in early-stage favourable Hodgkin lymphoma](https://onco.cc/key-papers/paper-ghsg-hd10-reduced-intensity-early-hodgkin-nejm-2010/), [Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma](https://onco.cc/key-papers/paper-glofitamab-dlbcl-n-engl-j-med-2022/), [GOG 120: concurrent cisplatin-based chemotherapy with radiotherapy for locally advanced cervical cancer](https://onco.cc/key-papers/paper-rose-cisplatin-chemoradiation-cervical-nejm-1999/), [GOG 240: bevacizumab added to chemotherapy for advanced cervical cancer](https://onco.cc/key-papers/paper-gog-240-bevacizumab-cervical-nejm-2014/), [Hearing improvement after bevacizumab in patients with neurofibromatosis type 2](https://onco.cc/key-papers/paper-plotkin-bevacizumab-nf2-nejm-2009/), [HER2CLIMB: tucatinib with trastuzumab and capecitabine for HER2-positive metastatic breast cancer, including brain metastases](https://onco.cc/key-papers/paper-her2climb-nejm-2020/), [High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison](https://onco.cc/key-papers/paper-moertel-n-engl-j-med/), [Hodi 2010: ipilimumab, the first checkpoint inhibitor, extends survival in metastatic melanoma](https://onco.cc/key-papers/paper-hodi-ipilimumab-melanoma-nejm-2010/), [Hospital volume and surgical mortality in the United States](https://onco.cc/key-papers/paper-birkmeyer-n-engl-j-med/), [HPV screening for cervical cancer in rural India (Osmanabad)](https://onco.cc/key-papers/paper-sankaranarayanan-hpv-screening-nejm-2009/), [Human papillomavirus and survival of patients with oropharyngeal cancer (RTOG 0129)](https://onco.cc/key-papers/paper-ang-hpv-oropharyngeal-nejm-2010/), [IARC verdict: excess body fat causes 13 cancers](https://onco.cc/key-papers/paper-body-fatness-iarc-nejm-2016/), [Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia](https://onco.cc/key-papers/paper-jan-burger-n-engl-j-med-2015/), [Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma](https://onco.cc/key-papers/paper-shine-ibrutinib-bendamustine-rituximab-mantle-cell-nejm-2022/), [IFM 2009: lenalidomide, bortezomib and dexamethasone with or without upfront transplantation for myeloma](https://onco.cc/key-papers/paper-ifm-2009-attal-nejm-2017/), [IMbrave150: atezolizumab plus bevacizumab replaces sorafenib as first treatment for advanced liver cancer](https://onco.cc/key-papers/paper-imbrave150-nejm-2020/), [Imlunestrant with or without Abemaciclib in Advanced Breast Cancer](https://onco.cc/key-papers/paper-ember-3-n-engl-j-med-2025/), [Improved survival with preoperative radiotherapy in resectable rectal cancer (Swedish Rectal Cancer Trial)](https://onco.cc/key-papers/paper-swedish-rectal-cancer-trial-preoperative-radiotherapy-nejm-1997/), [IMvigor011: using a blood test for leftover cancer to decide who gets immunotherapy after bladder surgery](https://onco.cc/key-papers/paper-imvigor011-nejm-2025/), [Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer](https://onco.cc/key-papers/paper-inavo120-n-engl-j-med-2024/), [Increasing incidence of early-onset colorectal cancer (review)](https://onco.cc/key-papers/paper-sinicrope-early-onset-crc-nejm-2022/), [INDIGO: vorasidenib, the first targeted drug for IDH-mutant low-grade glioma](https://onco.cc/key-papers/paper-indigo-nejm-2023/), [Inherited DNA-repair gene mutations in men with metastatic prostate cancer](https://onco.cc/key-papers/paper-pritchard-inherited-dna-repair-metastatic-prostate-nejm-2016/), [innovaTV 301: tisotumab vedotin versus chemotherapy as second- or third-line therapy for recurrent cervical cancer](https://onco.cc/key-papers/paper-innovatv-301-tisotumab-nejm-2024/), [INO-VATE: inotuzumab ozogamicin, a CD22 antibody-drug conjugate, versus chemotherapy for relapsed adult B-cell ALL](https://onco.cc/key-papers/paper-ino-vate-inotuzumab-all-nejm-2016/), [Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer](https://onco.cc/key-papers/paper-eortc-22922-n-engl-j-med-2015/), [Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer](https://onco.cc/key-papers/paper-partridge-n-engl-j-med/), [INTUITT-NF2: brigatinib in NF2-related schwannomatosis with progressive tumours](https://onco.cc/key-papers/paper-intuitt-nf2-brigatinib-plotkin-nejm-2024/), [IRIS: imatinib versus interferon plus cytarabine as first treatment for chronic myeloid leukaemia](https://onco.cc/key-papers/paper-iris-imatinib-nejm-2003/), [Jaiswal: clonal haematopoiesis, the pre-leukaemic clones in most people over 70](https://onco.cc/key-papers/paper-jaiswal-chip-nejm-2014/), [JAVELIN Bladder 100: avelumab maintenance after first-line platinum chemotherapy in advanced urothelial cancer](https://onco.cc/key-papers/paper-javelin-bladder-100-nejm-2020/), [JULIET: tisagenlecleucel for adults with relapsed or refractory diffuse large B-cell lymphoma](https://onco.cc/key-papers/paper-juliet-tisagenlecleucel-dlbcl-nejm-2019/), [K-ras mutations and benefit from cetuximab in advanced colorectal cancer](https://onco.cc/key-papers/paper-karapetis-kras-cetuximab-colorectal-nejm-2008/), [KarMMa-3: ide-cel CAR-T versus standard regimens in triple-class-exposed relapsed myeloma](https://onco.cc/key-papers/paper-karmma-3-ide-cel-nejm-2023/), [KATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment](https://onco.cc/key-papers/paper-katherine-nejm-2019/), [KEYNOTE-054 (EORTC 1325): adjuvant pembrolizumab versus placebo in resected stage III melanoma](https://onco.cc/key-papers/paper-keynote-054-eggermont-nejm-2018/), [KEYNOTE-177: pembrolizumab instead of chemotherapy as first treatment for mismatch-repair-deficient metastatic colorectal cancer](https://onco.cc/key-papers/paper-keynote-177-nejm-2020/), [KEYNOTE-189: pembrolizumab plus chemotherapy as first treatment for non-squamous lung cancer without a driver mutation](https://onco.cc/key-papers/paper-keynote-189-nejm-2018/), [KEYNOTE-355: pembrolizumab plus chemotherapy for PD-L1-positive advanced triple-negative breast cancer](https://onco.cc/key-papers/paper-keynote-355-nejm-2022/), [KEYNOTE-426: pembrolizumab plus axitinib versus sunitinib for advanced renal cell carcinoma](https://onco.cc/key-papers/paper-keynote-426-nejm-2019/), [KEYNOTE-522: adding pembrolizumab before and after surgery in early triple-negative breast cancer](https://onco.cc/key-papers/paper-keynote-522-nejm-2022/), [KEYNOTE-564: a year of pembrolizumab after kidney cancer surgery](https://onco.cc/key-papers/paper-keynote-564-nejm-2021/), [KEYNOTE-689: neoadjuvant and adjuvant pembrolizumab for resectable locally advanced head and neck cancer](https://onco.cc/key-papers/paper-keynote-689-nejm-2025/), [KEYNOTE-775: lenvatinib plus pembrolizumab versus chemotherapy for previously treated advanced endometrial cancer](https://onco.cc/key-papers/paper-keynote-775-nejm-2022/), [KEYNOTE-826: pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer](https://onco.cc/key-papers/paper-keynote-826-nejm-2021/), [Korea's thyroid-cancer "epidemic"--screening and overdiagnosis](https://onco.cc/key-papers/paper-ahn-n-engl-j-med/), [KRYSTAL-1: adagrasib with or without cetuximab in KRAS G12C-mutated colorectal cancer](https://onco.cc/key-papers/paper-krystal-1-crc-yaeger-nejm-2023/), [LACC: minimally invasive versus open radical hysterectomy for early cervical cancer](https://onco.cc/key-papers/paper-lacc-nejm-2018/), [Larotrectinib in TRK fusion-positive cancers in adults and children](https://onco.cc/key-papers/paper-drilon-larotrectinib-nejm-2018/), [LATITUDE: abiraterone plus prednisone in newly diagnosed high-risk metastatic castration-sensitive prostate cancer](https://onco.cc/key-papers/paper-latitude-nejm-2017/), [Le 2015: PD-1 blockade works in tumours with mismatch-repair deficiency, whatever the organ](https://onco.cc/key-papers/paper-le-mmr-deficiency-pd1-nejm-2015/), [Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma](https://onco.cc/key-papers/paper-lenalidomide-multiple-myeloma-n-engl-j-med-2007/), [Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma](https://onco.cc/key-papers/paper-moertel-levamisole-fluorouracil-adjuvant-colon-nejm-1990/), [LIBRETTO-001: selpercatinib in RET fusion-positive non-small-cell lung cancer](https://onco.cc/key-papers/paper-libretto-001-selpercatinib-nsclc-nejm-2020/), [LIBRETTO-431: first-line selpercatinib versus chemotherapy with or without pembrolizumab in RET fusion-positive lung cancer](https://onco.cc/key-papers/paper-libretto-431-nejm-2023/), [LIBRETTO-531: selpercatinib versus cabozantinib or vandetanib in advanced RET-mutant medullary thyroid cancer](https://onco.cc/key-papers/paper-libretto-531-nejm-2023/), [Liver transplantation for small hepatocellular carcinomas in patients with cirrhosis (the Milan criteria)](https://onco.cc/key-papers/paper-mazzaferro-milan-criteria-nejm-1996/), [Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer](https://onco.cc/key-papers/paper-calgb-140503-n-engl-j-med-2023/), [Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer](https://onco.cc/key-papers/paper-alascca-n-engl-j-med-2025/), [Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer](https://onco.cc/key-papers/paper-hughes-n-engl-j-med/), [Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes](https://onco.cc/key-papers/paper-amer-zeidan-n-engl-j-med-2020/), [MAIA: adding daratumumab to lenalidomide-dexamethasone for older patients with newly diagnosed myeloma who cannot have a transplant](https://onco.cc/key-papers/paper-maia-daratumumab-rd-nejm-2019/), [MajesTEC-1: teclistamab, an off-the-shelf BCMA bispecific antibody, in heavily pretreated myeloma](https://onco.cc/key-papers/paper-majestec-1-teclistamab-nejm-2022/), [Management of lung nodules detected by volume CT scanning](https://onco.cc/key-papers/paper-van-klaveren-n-engl-j-med/), [MARIPOSA: amivantamab plus lazertinib versus osimertinib as first treatment for EGFR-mutated lung cancer](https://onco.cc/key-papers/paper-mariposa-nejm-2024/), [Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both](https://onco.cc/key-papers/paper-woodcock-n-engl-j-med/), [MATTERHORN: perioperative durvalumab with FLOT chemotherapy for resectable gastric and gastro-oesophageal junction cancer](https://onco.cc/key-papers/paper-matterhorn-nejm-2025/), [Maude 2014: CD19 CAR-T cells produce complete remission in 27 of 30 children and adults with relapsed ALL](https://onco.cc/key-papers/paper-maude-ctl019-all-nejm-2014/), [Measurement of prostate-specific antigen in serum as a screening test for prostate cancer](https://onco.cc/key-papers/paper-catalona-psa-screening-test-nejm-1991/), [Methylnaltrexone for opioid-induced constipation in advanced illness (MNTX 302)](https://onco.cc/key-papers/paper-mntx-302-thomas-nejm-2008/), [Minnesota trial: a yearly stool blood test cuts bowel cancer deaths by a third](https://onco.cc/key-papers/paper-minnesota-fobt-nejm-1993/), [MIRASOL: mirvetuximab soravtansine versus chemotherapy in folate receptor alpha-high platinum-resistant ovarian cancer](https://onco.cc/key-papers/paper-mirasol-nejm-2023/), [Molecular measurable residual disease in NPM1-mutated acute myeloid leukaemia (UK NCRI AML17)](https://onco.cc/key-papers/paper-ivey-npm1-mrd-nejm-2016/), [MonumenTAL-1: talquetamab, a GPRC5D-directed bispecific antibody for relapsed multiple myeloma](https://onco.cc/key-papers/paper-monumental-1-talquetamab-nejm-2022/), [MSLT-II: completion lymph node dissection or observation for sentinel-node metastasis in melanoma](https://onco.cc/key-papers/paper-mslt-ii-faries-nejm-2017/), [Mucinous ovarian carcinoma (review)](https://onco.cc/key-papers/paper-morice-mucinous-ovarian-carcinoma-nejm-2019/), [Multitarget stool DNA testing for colorectal-cancer screening](https://onco.cc/key-papers/paper-imperiale-multitarget-stool-dna-screening-nejm-2014/), [MURANO: two years of venetoclax plus rituximab versus chemo-immunotherapy in relapsed CLL](https://onco.cc/key-papers/paper-murano-venetoclax-rituximab-nejm-2018/), [Mutation of FOXL2 in granulosa cell tumours of the ovary](https://onco.cc/key-papers/paper-shah-foxl2-granulosa-nejm-2009/), [Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer](https://onco.cc/key-papers/paper-taplin-ar-mutation-androgen-independent-prostate-nejm-1995/), [Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma](https://onco.cc/key-papers/paper-zaretsky-n-engl-j-med/), [NADINA: two doses of ipilimumab plus nivolumab before surgery beat a year of nivolumab after surgery in stage III melanoma](https://onco.cc/key-papers/paper-nadina-nejm-2024/), [NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer](https://onco.cc/key-papers/paper-natalee-nejm-2024/), [NELSON: volume-based CT screening reduces lung cancer deaths with fewer false alarms](https://onco.cc/key-papers/paper-nelson-nejm-2020/), [Neoadjuvant cemiplimab for stage II to IV cutaneous squamous cell carcinoma](https://onco.cc/key-papers/paper-gross-neoadjuvant-cemiplimab-cscc-nejm-2022/), [Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma](https://onco.cc/key-papers/paper-swog-s1801-n-engl-j-med-2023/), [NETTER-1: 177Lu-Dotatate for midgut neuroendocrine tumours progressing on octreotide](https://onco.cc/key-papers/paper-netter-1-nejm-2017/), [Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening](https://onco.cc/key-papers/paper-blue-c-n-engl-j-med-2024/), [NIAGARA: durvalumab before and after cystectomy for muscle-invasive bladder cancer](https://onco.cc/key-papers/paper-niagara-nejm-2024/), [NICHE-2: a month of nivolumab and ipilimumab before surgery clears mismatch-repair-deficient colon cancer in most patients](https://onco.cc/key-papers/paper-niche-2-nejm-2024/), [Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer](https://onco.cc/key-papers/paper-niraparib-ovarian-n-engl-j-med-2016/), [Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors](https://onco.cc/key-papers/paper-gounder-n-engl-j-med/), [Nivolumab in previously untreated melanoma without BRAF mutation](https://onco.cc/key-papers/paper-braf-melanoma-n-engl-j-med-2015/), [Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer](https://onco.cc/key-papers/paper-keunchil-park-n-engl-j-med-2019/), [Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden](https://onco.cc/key-papers/paper-checkmate-227-n-engl-j-med-2018/), [Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer (CheckMate 8HW)](https://onco.cc/key-papers/paper-andre-checkmate-8hw-nivolumab-ipilimumab-nejm-2024/), [NLST: yearly low-dose CT scans cut lung cancer deaths in heavy smokers](https://onco.cc/key-papers/paper-nlst-nejm-2011/), [Nonoperative management of mismatch repair-deficient tumors](https://onco.cc/key-papers/paper-cercek-nonoperative-management-mismatch-repair-deficient-tumours-nejm-2025/), [NordICC: inviting people to a screening colonoscopy reduced bowel cancer, but less than expected](https://onco.cc/key-papers/paper-nordicc-nejm-2022/), [North American Intergroup: all-trans retinoic acid in acute promyelocytic leukaemia](https://onco.cc/key-papers/paper-tallman-atra-apl-nejm-1997/), [NRG-GY018: pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer](https://onco.cc/key-papers/paper-nrg-gy018-nejm-2023/), [Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting](https://onco.cc/key-papers/paper-navari-n-engl-j-med/), [OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer](https://onco.cc/key-papers/paper-olympia-nejm-2021/), [OlympiAD: olaparib versus chemotherapy in metastatic breast cancer with a germline BRCA mutation](https://onco.cc/key-papers/paper-olympiad-nejm-2017/), [Omitting Radiotherapy after Breast-Conserving Surgery in Luminal A Breast Cancer](https://onco.cc/key-papers/paper-lumina-n-engl-j-med-2023/), [Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC](https://onco.cc/key-papers/paper-lu-laura-osimertinib-stage-iii-nejm-2024/), [Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer](https://onco.cc/key-papers/paper-osimertinib-nsclc-n-engl-j-med-2017/), [Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC](https://onco.cc/key-papers/paper-planchard-flaura2-osimertinib-chemotherapy-nejm-2023/), [Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma](https://onco.cc/key-papers/paper-imcgp100-202-n-engl-j-med-2021/), [Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC](https://onco.cc/key-papers/paper-pacific-n-engl-j-med-2018-update/), [Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer](https://onco.cc/key-papers/paper-inavo120-n-engl-j-med-2025-update/), [Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer](https://onco.cc/key-papers/paper-checkmate-816-n-engl-j-med-2025-update/), [Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC](https://onco.cc/key-papers/paper-osimertinib-nsclc-n-engl-j-med-2020/), [Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer](https://onco.cc/key-papers/paper-keynote-522-n-engl-j-med-2024-update/), [Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer](https://onco.cc/key-papers/paper-monaleesa-2-n-engl-j-med-2022-update/), [Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer (MOSAIC)](https://onco.cc/key-papers/paper-mosaic-oxaliplatin-adjuvant-colon-nejm-2004/), [PACE: ponatinib in Philadelphia chromosome-positive leukaemias resistant to earlier tyrosine kinase inhibitors](https://onco.cc/key-papers/paper-pace-ponatinib-nejm-2013/), [PACIFIC: a year of durvalumab after chemoradiotherapy for stage III lung cancer](https://onco.cc/key-papers/paper-pacific-nejm-2017/), [Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer](https://onco.cc/key-papers/paper-sandler-ecog-4599-bevacizumab-nsclc-nejm-2006/), [Palbociclib and Letrozole in Advanced Breast Cancer](https://onco.cc/key-papers/paper-paloma-2-n-engl-j-med-2016/), [Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer](https://onco.cc/key-papers/paper-patina-n-engl-j-med-2026/), [Pancreatic cancer](https://onco.cc/key-papers/paper-hidalgo-pancreatic-cancer-review-nejm-2010/), [Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer (PRIME)](https://onco.cc/key-papers/paper-douillard-prime-panitumumab-ras-nejm-2013/), [PAOLA-1: olaparib added to bevacizumab maintenance in newly diagnosed ovarian cancer, with benefit confined to HRD-positive tumours](https://onco.cc/key-papers/paper-paola-1-nejm-2019/), [PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer](https://onco.cc/key-papers/paper-nct04821622-n-engl-j-med-2026/), [PD-1 blockade with cemiplimab in advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1)](https://onco.cc/key-papers/paper-empower-cscc-1-cemiplimab-migden-nejm-2018/), [PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma](https://onco.cc/key-papers/paper-keynote-017-n-engl-j-med-2016/), [Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy](https://onco.cc/key-papers/paper-amant-n-engl-j-med/), [Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma](https://onco.cc/key-papers/paper-pembrolizumab-urothelial-n-engl-j-med-2017/), [Pembrolizumab for Early Triple-Negative Breast Cancer](https://onco.cc/key-papers/paper-keynote-522-n-engl-j-med-2020/), [Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer](https://onco.cc/key-papers/paper-keynote-407-n-engl-j-med-2018/), [Perioperative Apalutamide in High-Risk Localized Prostate Cancer](https://onco.cc/key-papers/paper-nct03767244-n-engl-j-med-2026/), [Perioperative durvalumab for resectable non-small-cell lung cancer](https://onco.cc/key-papers/paper-heymach-aegean-perioperative-durvalumab-nejm-2023/), [Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer](https://onco.cc/key-papers/paper-provencio-nadim-ii-perioperative-nivolumab-stage-iii-nejm-2023/), [Perioperative Nivolumab in Resectable Lung Cancer](https://onco.cc/key-papers/paper-nct04025879-n-engl-j-med-2024/), [Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer](https://onco.cc/key-papers/paper-keynote-671-n-engl-j-med-2023/), [PERSEUS: daratumumab added to bortezomib-lenalidomide-dexamethasone around autologous transplant in newly diagnosed myeloma](https://onco.cc/key-papers/paper-perseus-dara-vrd-transplant-nejm-2024/), [Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer](https://onco.cc/key-papers/paper-cleopatra-n-engl-j-med-2012/), [Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors](https://onco.cc/key-papers/paper-nct04585750-n-engl-j-med-2026/), [Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer](https://onco.cc/key-papers/paper-van-as-n-engl-j-med/), [PIVOT: follow-up of prostatectomy versus observation for early prostate cancer](https://onco.cc/key-papers/paper-wilt-pivot-prostatectomy-observation-nejm-2017/), [PLCO: mortality results from a randomised prostate cancer screening trial](https://onco.cc/key-papers/paper-andriole-plco-prostate-screening-nejm-2009/), [POLARIX: swapping vincristine for the antibody-drug conjugate polatuzumab vedotin in first-line treatment of diffuse large B-cell lymphoma](https://onco.cc/key-papers/paper-polarix-polatuzumab-rchp-nejm-2022/), [POLO: maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer](https://onco.cc/key-papers/paper-polo-olaparib-maintenance-gbrca-pancreatic-nejm-2019/), [Ponsegromab for the Treatment of Cancer Cachexia](https://onco.cc/key-papers/paper-groarke-ponsegromab-cancer-cachexia-nejm-2024/), [Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial](https://onco.cc/key-papers/paper-overgaard-n-engl-j-med/), [PRECISION: MRI-targeted or standard biopsy for prostate cancer diagnosis](https://onco.cc/key-papers/paper-precision-mri-targeted-biopsy-nejm-2018/), [Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer (Dutch TME trial)](https://onco.cc/key-papers/paper-kapiteijn-dutch-tme-preoperative-radiotherapy-nejm-2001/), [PREVAIL: enzalutamide in metastatic prostate cancer before chemotherapy](https://onco.cc/key-papers/paper-beer-prevail-enzalutamide-nejm-2014/), [PRIMA: niraparib maintenance in newly diagnosed advanced ovarian cancer](https://onco.cc/key-papers/paper-prima-niraparib-nejm-2019/), [PRODIGE 24/CCTG PA6: adjuvant modified FOLFIRINOX versus gemcitabine after resection of pancreatic cancer](https://onco.cc/key-papers/paper-prodige-24-adjuvant-mfolfirinox-pancreatic-nejm-2018/), [PROfound: olaparib for metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations](https://onco.cc/key-papers/paper-profound-nejm-2020/), [Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission](https://onco.cc/key-papers/paper-auperin-prophylactic-cranial-irradiation-sclc-nejm-1999/), [Prophylactic cranial irradiation in extensive small-cell lung cancer](https://onco.cc/key-papers/paper-slotman-n-engl-j-med/), [PROSPECT: neoadjuvant FOLFOX with selective use of chemoradiotherapy for locally advanced rectal cancer](https://onco.cc/key-papers/paper-prospect-nejm-2023/), [PROSPER: enzalutamide in men with non-metastatic castration-resistant prostate cancer](https://onco.cc/key-papers/paper-prosper-nejm-2018/), [Prostate Cancer Screening with PSA and MRI Followed by Targeted Biopsy Only](https://onco.cc/key-papers/paper-goteborg-2-n-engl-j-med-2022/), [Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate](https://onco.cc/key-papers/paper-stamey-psa-serum-marker-nejm-1987/), [ProtecT: 10-year outcomes after monitoring, surgery or radiotherapy for localised prostate cancer](https://onco.cc/key-papers/paper-protect-nejm-2016/), [ProtecT: fifteen-year outcomes after monitoring, surgery or radiotherapy for prostate cancer](https://onco.cc/key-papers/paper-protect-15-year-nejm-2023/), [Quality indicators for colonoscopy and the risk of interval cancer](https://onco.cc/key-papers/paper-kaminski-adenoma-detection-rate-interval-cancer-nejm-2010/), [QUAZAR AML-001: oral azacitidine maintenance for acute myeloid leukaemia in first remission](https://onco.cc/key-papers/paper-quazar-aml-001-wei-nejm-2020/), [RADIANT-3: everolimus for advanced pancreatic neuroendocrine tumours](https://onco.cc/key-papers/paper-radiant-3-everolimus-pnet-yao-nejm-2011/), [Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer](https://onco.cc/key-papers/paper-rtog-9601-n-engl-j-med-2017/), [Radiotherapy plus cetuximab for locoregionally advanced squamous cell carcinoma of the head and neck](https://onco.cc/key-papers/paper-bonner-cetuximab-radiotherapy-nejm-2006/), [Randomized trial of TAS-102 for refractory metastatic colorectal cancer (RECOURSE)](https://onco.cc/key-papers/paper-mayer-recourse-tas-102-nejm-2015/), [RAPID: PET-directed therapy for early-stage Hodgkin lymphoma](https://onco.cc/key-papers/paper-rapid-pet-directed-therapy-early-hodgkin-nejm-2015/), [RATHL: adapted treatment guided by interim PET-CT in advanced Hodgkin lymphoma](https://onco.cc/key-papers/paper-rathl-interim-pet-adapted-abvd-advanced-hodgkin-nejm-2016/), [RATIFY: midostaurin added to chemotherapy for acute myeloid leukaemia with a FLT3 mutation](https://onco.cc/key-papers/paper-ratify-midostaurin-nejm-2017/), [Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer](https://onco.cc/key-papers/paper-armstrong-n-engl-j-med/), [Regional Nodal Irradiation in Early-Stage Breast Cancer](https://onco.cc/key-papers/paper-ma-20-n-engl-j-med-2015/), [Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy](https://onco.cc/key-papers/paper-brown-n-engl-j-med/), [Regulatory review of novel therapeutics--comparison of three regulatory agencies](https://onco.cc/key-papers/paper-downing-n-engl-j-med/), [RELATIVITY-047: relatlimab plus nivolumab, the first LAG-3 checkpoint combination, in untreated advanced melanoma](https://onco.cc/key-papers/paper-relativity-047-nejm-2022/), [RELEVANCE: rituximab plus lenalidomide in advanced untreated follicular lymphoma](https://onco.cc/key-papers/paper-relevance-rituximab-lenalidomide-follicular-lymphoma-morschhauser-nejm-2018/), [Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F](https://onco.cc/key-papers/paper-shaw-alk-l1198f-resensitisation-nejm-2016/), [Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer](https://onco.cc/key-papers/paper-monaleesa-2-n-engl-j-med-2016/), [Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma](https://onco.cc/key-papers/paper-lyma-rituximab-maintenance-after-transplant-mantle-cell-nejm-2017/), [Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children](https://onco.cc/key-papers/paper-minard-colin-n-engl-j-med/), [Rohaas 2022: the first randomised trial of TIL therapy, against ipilimumab, in advanced melanoma](https://onco.cc/key-papers/paper-rohaas-til-vs-ipilimumab-nejm-2022/), [RTOG 91-11: concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer](https://onco.cc/key-papers/paper-rtog-91-11-forastiere-nejm-2003/), [RTOG 9408: radiotherapy with short-term androgen deprivation for localised prostate cancer](https://onco.cc/key-papers/paper-rtog-9408-short-term-adt-jones-nejm-2011/), [RTOG 9501: postoperative concurrent radiotherapy and chemotherapy for high-risk head and neck squamous cell carcinoma](https://onco.cc/key-papers/paper-cooper-rtog-9501-nejm-2004/), [RTOG 9802: radiation plus procarbazine, lomustine and vincristine in high-risk low-grade glioma](https://onco.cc/key-papers/paper-rtog-9802-buckner-nejm-2016/), [RUBY: dostarlimab with chemotherapy for advanced or recurrent endometrial cancer](https://onco.cc/key-papers/paper-ruby-nejm-2023/), [Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer](https://onco.cc/key-papers/paper-ascent-03-n-engl-j-med-2025/), [Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer](https://onco.cc/key-papers/paper-ascent-04-n-engl-j-med-2026/), [Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer](https://onco.cc/key-papers/paper-sacituzumab-govitecan-tnbc-n-engl-j-med-2019/), [Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR -Mutated Advanced NSCLC](https://onco.cc/key-papers/paper-nct05870319-n-engl-j-med-2026/), [Safety and activity of anti-PD-L1 antibody in patients with advanced cancer](https://onco.cc/key-papers/paper-brahmer-anti-pd-l1-phase-1-nejm-2012/), [Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma](https://onco.cc/key-papers/paper-schaapveld-second-cancer-risk-40-years-hodgkin-nejm-2015/), [Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma](https://onco.cc/key-papers/paper-belinda-tisagenlecleucel-second-line-nejm-2022/), [SELECT: lenvatinib versus placebo in radioiodine-refractory differentiated thyroid cancer](https://onco.cc/key-papers/paper-select-lenvatinib-nejm-2015/), [Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer](https://onco.cc/key-papers/paper-nct04819100-n-engl-j-med-2026/), [Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes](https://onco.cc/key-papers/paper-lincoff-n-engl-j-med/), [Setmelanotide for the treatment of acquired hypothalamic obesity (TRANSCEND)](https://onco.cc/key-papers/paper-transcend-miller-nejm-2026/), [Sevabertinib in Advanced HER2 -Mutant Non-Small-Cell Lung Cancer](https://onco.cc/key-papers/paper-soho-01-n-engl-j-med-2025/), [SHAPE: simple versus radical hysterectomy in low-risk early cervical cancer](https://onco.cc/key-papers/paper-shape-nejm-2024/), [SHARP: sorafenib in advanced hepatocellular carcinoma](https://onco.cc/key-papers/paper-sharp-sorafenib-nejm-2008/), [Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma](https://onco.cc/key-papers/paper-perry-n-engl-j-med/), [SIOPEL-3: cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma](https://onco.cc/key-papers/paper-siopel-3-cisplatin-vs-plado-standard-risk-hepatoblastoma-perilongo-nejm-2009/), [Sipuleucel-T immunotherapy for castration-resistant prostate cancer](https://onco.cc/key-papers/paper-kantoff-n-engl-j-med/), [Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss](https://onco.cc/key-papers/paper-brock-n-engl-j-med/), [SOLAR-1: alpelisib plus fulvestrant for PIK3CA-mutated hormone receptor-positive advanced breast cancer](https://onco.cc/key-papers/paper-solar-1-alpelisib-nejm-2019/), [SOLO-1: two years of olaparib maintenance after first-line chemotherapy for BRCA-mutated ovarian cancer](https://onco.cc/key-papers/paper-solo-1-nejm-2018/), [Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma](https://onco.cc/key-papers/paper-shattuck-n-engl-j-med/), [Sotorasib for Lung Cancers with KRAS p.G12C Mutation](https://onco.cc/key-papers/paper-kras-nsclc-n-engl-j-med-2021/), [SPARTAN: apalutamide for non-metastatic castration-resistant prostate cancer](https://onco.cc/key-papers/paper-spartan-nejm-2018/), [SPCG-4: radical prostatectomy or watchful waiting in prostate cancer, 29-year follow-up](https://onco.cc/key-papers/paper-bill-axelson-spcg-4-29-year-nejm-2018/), [STAMPEDE: adding abiraterone to hormone therapy at diagnosis of advanced prostate cancer](https://onco.cc/key-papers/paper-stampede-abiraterone-nejm-2017/), [Stupp 2005: temozolomide added to radiotherapy for newly diagnosed glioblastoma](https://onco.cc/key-papers/paper-stupp-temozolomide-nejm-2005/), [Sunitinib malate for the treatment of pancreatic neuroendocrine tumours](https://onco.cc/key-papers/paper-raymond-sunitinib-pnet-nejm-2011/), [Supplemental MRI Screening for Women with Extremely Dense Breast Tissue](https://onco.cc/key-papers/paper-bakker-n-engl-j-med/), [Swedish registry study: HPV vaccination almost eliminates cervical cancer when given before 17](https://onco.cc/key-papers/paper-hpv-vaccine-sweden-nejm-2020/), [SWOG 8710: neoadjuvant MVAC chemotherapy before cystectomy for muscle-invasive bladder cancer](https://onco.cc/key-papers/paper-swog-8710-neoadjuvant-mvac-nejm-2003/), [SWOG 9346: intermittent versus continuous androgen deprivation in metastatic prostate cancer](https://onco.cc/key-papers/paper-hussain-swog-9346-intermittent-androgen-deprivation-nejm-2013/), [SWOG 9916: docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer](https://onco.cc/key-papers/paper-petrylak-swog-9916-docetaxel-estramustine-nejm-2004/), [SWOG S1826: nivolumab plus AVD chemotherapy versus brentuximab-AVD for advanced Hodgkin lymphoma in adolescents and adults](https://onco.cc/key-papers/paper-swog-s1826-nivolumab-avd-nejm-2024/), [Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm](https://onco.cc/key-papers/paper-pemmaraju-n-engl-j-med/), [TAILORx: adjuvant chemotherapy guided by the 21-gene recurrence score in hormone receptor-positive, node-negative breast cancer](https://onco.cc/key-papers/paper-tailorx-nejm-2018/), [Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation](https://onco.cc/key-papers/paper-embraca-n-engl-j-med-2018/), [Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy](https://onco.cc/key-papers/paper-nct06612151-n-engl-j-med-2026/), [Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukaemia](https://onco.cc/key-papers/paper-roberts-ph-like-all-nejm-2014/), [Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy](https://onco.cc/key-papers/paper-tarlatamab-sclc-n-engl-j-med-2025/), [TAX 327: docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer](https://onco.cc/key-papers/paper-tannock-tax-327-docetaxel-prednisone-nejm-2004/), [Temel: early palliative care alongside chemotherapy improved quality of life, mood and survival in lung cancer](https://onco.cc/key-papers/paper-temel-early-palliative-care-nejm-2010/), [The effect of group psychosocial support on survival in metastatic breast cancer](https://onco.cc/key-papers/paper-goodwin-n-engl-j-med/), [The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews](https://onco.cc/key-papers/paper-struewing-brca-founder-mutations-ashkenazi-nejm-1997/), [The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma](https://onco.cc/key-papers/paper-rosenwald-molecular-profiling-dlbcl-nejm-2002/), [Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma](https://onco.cc/key-papers/paper-imcgp100-202-n-engl-j-med-2023-update/), [Topalian 2012: the first large trial of a PD-1 antibody shows durable responses across melanoma, lung and kidney cancer](https://onco.cc/key-papers/paper-topalian-anti-pd1-nejm-2012/), [TOPARP-A: DNA-repair defects and olaparib in metastatic prostate cancer](https://onco.cc/key-papers/paper-mateo-toparp-a-olaparib-dna-repair-nejm-2015/), [TRACERx first 100: tracking how lung cancers evolve, and how chromosomal chaos predicts relapse](https://onco.cc/key-papers/paper-tracerx-100-nejm-2017/), [Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer](https://onco.cc/key-papers/paper-hera-b31-n9831-n-engl-j-med-2005/), [Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer](https://onco.cc/key-papers/paper-trastuzumab-deruxtecan-breast-her2-positive-n-engl-j-med-2020/), [Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer](https://onco.cc/key-papers/paper-destiny-breast05-n-engl-j-med-2026/), [Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer](https://onco.cc/key-papers/paper-destiny-breast09-n-engl-j-med-2026/), [Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer](https://onco.cc/key-papers/paper-trastuzumab-breast-her2-positive-n-engl-j-med-2005/), [Treatment of disseminated germ cell tumours with cisplatin, bleomycin and either vinblastine or etoposide](https://onco.cc/key-papers/paper-williams-bep-vs-pvb-nejm-1987/), [TRIDENT-1: repotrectinib in ROS1 fusion-positive non-small-cell lung cancer](https://onco.cc/key-papers/paper-trident-1-repotrectinib-nejm-2024/), [Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer (SUNLIGHT)](https://onco.cc/key-papers/paper-prager-sunlight-trifluridine-tipiracil-bevacizumab-nejm-2023/), [TRITON3: rucaparib or physician's choice in metastatic castration-resistant prostate cancer](https://onco.cc/key-papers/paper-fizazi-triton3-rucaparib-nejm-2023/), [Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing](https://onco.cc/key-papers/paper-dvorak-n-engl-j-med/), [Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide](https://onco.cc/key-papers/paper-turrisi-twice-daily-thoracic-radiotherapy-limited-sclc-nejm-1999/), [Underrepresentation of patients 65 years of age or older in cancer-treatment trials](https://onco.cc/key-papers/paper-hutchins-n-engl-j-med/), [Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors](https://onco.cc/key-papers/paper-liu-n-engl-j-med/), [Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations](https://onco.cc/key-papers/paper-braf-thyroid-n-engl-j-med-2015/), [Vestibular schwannomas (review)](https://onco.cc/key-papers/paper-carlson-link-vestibular-schwannomas-nejm-2021/), [VIALE-A: venetoclax plus azacitidine for older adults with acute myeloid leukaemia who cannot have intensive chemotherapy](https://onco.cc/key-papers/paper-viale-a-venetoclax-azacitidine-nejm-2020/), [VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer](https://onco.cc/key-papers/paper-vision-nejm-2021/), [VISION: tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations](https://onco.cc/key-papers/paper-vision-tepotinib-paik-nejm-2020/), [Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease](https://onco.cc/key-papers/paper-manson-n-engl-j-med/), [Weight lifting in women with breast-cancer-related lymphedema](https://onco.cc/key-papers/paper-schmitz-n-engl-j-med/), [Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia](https://onco.cc/key-papers/paper-zanubrutinib-cll-n-engl-j-med-2023/), [ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma](https://onco.cc/key-papers/paper-zuma-1-axi-cel-nejm-2017/), [ZUMA-2: brexu-cel CAR-T for mantle cell lymphoma that has failed BTK inhibitors](https://onco.cc/key-papers/paper-zuma-2-brexu-cel-mantle-cell-nejm-2020/), [ZUMA-7: axi-cel CAR-T instead of salvage chemotherapy and transplant for large B-cell lymphoma that relapses early](https://onco.cc/key-papers/paper-zuma-7-axi-cel-second-line-nejm-2022/)
- people: [Chak-sing Lau](https://onco.cc/people/chak-sing-lau/), [Chong-Jen Yu](https://onco.cc/people/chong-jen-yu/), [Christiane Pott](https://onco.cc/people/christiane-pott/), [Taofeek K. Owonikoko](https://onco.cc/people/taofeek-owonikoko/), [Yoram G. Weiss](https://onco.cc/people/yoram-weiss/)

---
JSON: https://onco.cc/api/v1/entities/nejm.json